Pharmaceuticals News and Research

RSS

Clues about how alcoholic behavior is “switched” on

As part of an ongoing effort to understand the biochemical basis of alcohol abuse, scientists at the U.S. Department of Energy’s Brookhaven National Laboratory have published two studies on how modulating receptors for dopamine - a chemical “signaler” in the brain’s reward circuits - affects drinking behavior in mice and rats.

9 May 2005

Global epidemic of avian flu - Governments bury their heads

Governments around the world must stop burying their heads in the sand over the growing threat of a global epidemic of avian flu, argues a GP in this week's BMJ.

5 May 2005

Research is first to test effectiveness of a new patch for treating ADHD

A new University at Buffalo study of treatments for children with attention deficit hyperactivity disorder (ADHD) has found that combining behavior modification therapy with medication is the most effective way to improve the behavior of many ADHD children.

5 May 2005

New discovery could improve IVF results

Scientists in the U.S. think they may have solved the puzzle of why some embryos fail to implant in their mother's womb, which is one of the main causes of IVF failures.

4 May 2005

Specific variants of genes predict bleeding after heart surgery

Duke University Medical Center researchers have found that the presence of specific variants of genes that control clotting and the contractility, or "tone," of blood vessels can double the ability of physicians to predict those heart surgery patients at greatest risk of bleeding after surgery.

4 May 2005

Vaccine developed at Rockefeller University boosts natural killer T cells in patients with cancer

A new vaccine designed at The Rockefeller University boosted a type of fast-responding immune system cell called the natural killer T (NKT) cell in patients with advanced cancer. The study surprised researchers by revealing the ability of these NKT cells to spur other, slower-responding immune cells to go to work.

4 May 2005

Monitoring program has successfully identified a large number of previously unknown, serious and often-fatal drug reactions

A monitoring program developed by a Northwestern University researcher has successfully identified a large number of previously unknown, serious and often-fatal drug reactions associated with 15 commonly used drugs, including Plavix®, thalidomide and drug-coated cardiac stents.

3 May 2005

Critical lock and key mechanism found for the assembly of tumor blood vessels

A critical lock and key mechanism that allows the final step in the completion of new blood vessel formation has been identified by a University of California, San Diego (UCSD) School of Medicine team in research that promises to lead to a new way to halt tumor growth by cutting off the tumor blood supply.

3 May 2005

New drug may help treat certain forms of leukemia

A new experimental drug may be effective against a certain form of leukemia resistant to current treatments, research at UT Southwestern Medical Center shows.

2 May 2005

Fusing physics with medicine to fight cancer

Everyone’s lives are touched by cancer - it is a disease that affects 1 in 3 of us throughout our lifetime. Future developments that lead to earlier diagnosis and more effective therapy lie in further successful collaboration between high energy physicists and the healthcare industry.

2 May 2005

FDA to change regulations regarding side-effect information in drug ads

The Food and Drug Administration is about to make it easier for you to understand both the benefits and risks of a prescription medication, it was revealed at the Second Annual Medical Liaison Seminar sponsored here by Scientific Advantage LLC.

2 May 2005

GlaxoSmithKline to acquire Corixa Corporation

GlaxoSmithKline has announced the execution of a definitive agreement pursuant to which GSK will acquire Corixa Corporation, a developer of innovative products that regulate immunity, based in Seattle, WA (USA).

2 May 2005

Judge calls GlaxoSmithKline 'high-handed' over legal action from Biota

A Supreme Court judge in Melbourne, Australia has described as "high-handed" the delay by global pharmaceutical firm GlaxoSmithKline (GSK) in filing a defence against legal action from Biota Holdings last Friday.

1 May 2005

FDA gives go-ahead for new diabetes treatment

Sufferers from adult-onset diabetes, the most common form of the disease, will soon be able to access a new injectable diabetes treatment which when used with oral drugs, should be more effective in controlling their blood sugar.

1 May 2005

Fiber supplements may lower cardiovascular risk in type 2 diabetics

Fiber supplements lower "bad" low-density lipoprotein (LDL) cholesterol and increase "good" high-density lipoprotein (HDL) cholesterol in people with type 2 diabetes, according to a study presented at the American Heart Association's Sixth Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.

1 May 2005

$577 million provided for new Alberta health and learning centre

Alberta has committed $577 million to build a world-class health and learning facility that will change the way patients are diagnosed and treated and how medical students are trained.

28 Apr 2005

International coalition works to develop a cocktail of drugs to combat Malaria

As Africa marks its own Malaria Day in recognition of the fact that it bears 90% of the deadly disease’s burden, an international research coalition is working to develop a cocktail of drugs that overcomes increasing resistance to conventional treatment exhibited by the elusive parasite.

27 Apr 2005

National study to evaluate the effectiveness Targacept

Wake Forest University School of Medicine is one of 15 centers nationwide recruiting participants for a research study to evaluate the effectiveness of an investigational drug as an oral treatment for age associated memory impairment (AAMI), a condition that is marked by memory loss and poor concentration.

27 Apr 2005

Generex Biotechnology receives Australian patent for vaccine technology to fight cancer and pandemic influenza

Generex Biotechnology announced today that its wholly owned subsidiary, Antigen Express, has received Australian Patent No. 778115 titled "Hybrid Peptides Modulate the Immune Response." Antigen Express is designing and testing such vaccine peptides for the control of cancer and infectious diseases with a particular focus on the pandemic H5N1 influenza, which has been reported in South East Asia.

26 Apr 2005

Use of positron emission tomography may eliminate more strenuous drug development trials with animals

A number of articles explore the use of positron emission tomography (PET) and small animal imaging—nonsurgical techniques that open the door to understanding and treating human diseases—in the April issue of the Society of Nuclear Medicine’s Journal of Nuclear Medicine.

26 Apr 2005